Literature summary for 3.5.1.6 extracted from

Kummer, D.; Froehlich, T.K.; Joerger, M.; Aebi, S.; Sistonen, J.; Amstutz, U.; Largiader, C.R.
Dihydropyrimidinase and beta-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity (2015), Pharmacogenomics, 16, 1367-1377 .

Search for more literature for 3.5.1.6

Application

Application	Comment	Organism
medicine	pharmacogenetic studies in patients receiving fluoropyrimidine-based chemotherapy should include genetic variants in dihydropyrimidinase (DPYS) and beta-ureidopropionase (UPB1), in addition to DPYD, to improve the understanding of their contribution to severe toxicity from fluoropyrimidine-based chemotherapy. Potential unknown underlying causal variants linked to the associated dihydropyrimidinase and beta-ureidopropionase variants may have a clinically relevant effect on fluoropyrimidine toxicity and should be investigated	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	Q9UBR1	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
3-ureidopropanoate + H2O	3-ureidopropanoate i.e. N-carbamoyl-beta-alanine	Homo sapiens	beta-alanine + CO2 + NH3	-	?

Synonyms

Synonyms	Comment	Organism
UPB1	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)